Single dose treatment with PARP-inhibitor INO-1001 improves aging-associated cardiac and vascular dysfunction
- 31 July 2007
- journal article
- Published by Elsevier BV in Experimental Gerontology
- Vol. 42 (7), 676-685
- https://doi.org/10.1016/j.exger.2007.01.013
Abstract
No abstract availableThis publication has 53 references indexed in Scilit:
- Clinical perspectives of PARP inhibitorsPharmacological Research, 2005
- Discovery of Potent Poly(ADP-ribose) Polymerase-1 Inhibitors from the Modification of Indeno[1,2-c]isoquinolinoneJournal of Medicinal Chemistry, 2005
- Role of Nitrosative Stress and Poly(ADP-ribose) Polymerase Activation in Myocardial Reperfusion InjuryCurrent Vascular Pharmacology, 2005
- Role of Oxidative-Nitrosative Stress and Downstream Pathways in Various Forms of Cardiomyopathy and Heart FailureCurrent Vascular Pharmacology, 2005
- Role of Oxidative and Nitrosative Stress, Longevity Genes and Poly(ADPribose) Polymerase in Cardiovascular Dysfunction Associated with AgingCurrent Vascular Pharmacology, 2005
- Nitrosative stress and pharmacological modulation of heart failureTrends in Pharmacological Sciences, 2005
- Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitorsNature Reviews Drug Discovery, 2005
- Poly(ADP-Ribose) Polymerase Promotes Cardiac Remodeling, Contractile Failure, and Translocation of Apoptosis-Inducing Factor in a Murine Experimental Model of Aortic Banding and Heart FailureThe Journal of pharmacology and experimental therapeutics, 2004
- Does acute improvement of endothelial dysfunction in coronary artery disease improve myocardial ischemia?: A double-blind comparison of parenteral D- and L-ArginineJournal of the American College of Cardiology, 1998
- Hydrogen peroxide release by mitochondria increases during agingMechanisms of Ageing and Development, 1991